159 related articles for article (PubMed ID: 21307087)
21. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.
Butler DC; Messer A
PLoS One; 2011; 6(12):e29199. PubMed ID: 22216210
[TBL] [Abstract][Full Text] [Related]
22. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
[TBL] [Abstract][Full Text] [Related]
24. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease.
Yohrling IV GJ; Jiang GC; DeJohn MM; Robertson DJ; Vrana KE; Cha JH
J Neurochem; 2002 Sep; 82(6):1416-23. PubMed ID: 12354289
[TBL] [Abstract][Full Text] [Related]
26. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo.
Huang B; Schiefer J; Sass C; Landwehrmeyer GB; Kosinski CM; Kochanek S
Hum Gene Ther; 2007 Apr; 18(4):303-11. PubMed ID: 17472569
[TBL] [Abstract][Full Text] [Related]
27. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.
Pouladi MA; Xie Y; Skotte NH; Ehrnhoefer DE; Graham RK; Kim JE; Bissada N; Yang XW; Paganetti P; Friedlander RM; Leavitt BR; Hayden MR
Hum Mol Genet; 2010 Apr; 19(8):1528-38. PubMed ID: 20097678
[TBL] [Abstract][Full Text] [Related]
28. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
29. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
[TBL] [Abstract][Full Text] [Related]
30. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.
Thomas EA; Coppola G; Tang B; Kuhn A; Kim S; Geschwind DH; Brown TB; Luthi-Carter R; Ehrlich ME
Hum Mol Genet; 2011 Mar; 20(6):1049-60. PubMed ID: 21177255
[TBL] [Abstract][Full Text] [Related]
31. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease.
Busch A; Engemann S; Lurz R; Okazawa H; Lehrach H; Wanker EE
J Biol Chem; 2003 Oct; 278(42):41452-61. PubMed ID: 12888569
[TBL] [Abstract][Full Text] [Related]
32. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.
Southwell AL; Ko J; Patterson PH
J Neurosci; 2009 Oct; 29(43):13589-602. PubMed ID: 19864571
[TBL] [Abstract][Full Text] [Related]
33. Analysis of proteolytic processes and enzymatic activities in the generation of huntingtin n-terminal fragments in an HEK293 cell model.
Tebbenkamp AT; Crosby KW; Siemienski ZB; Brown HH; Golde TE; Borchelt DR
PLoS One; 2012; 7(12):e50750. PubMed ID: 23236391
[TBL] [Abstract][Full Text] [Related]
34. Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice.
Pitzer M; Lueras J; Warden A; Weber S; McBride J
Brain Res; 2015 May; 1608():177-90. PubMed ID: 25732261
[TBL] [Abstract][Full Text] [Related]
35. Modulation of mutant Huntingtin aggregates and toxicity by human myeloid leukemia factors.
Banerjee M; Datta M; Bhattacharyya NP
Int J Biochem Cell Biol; 2017 Jan; 82():1-9. PubMed ID: 27840155
[TBL] [Abstract][Full Text] [Related]
36. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity.
Li H; Li SH; Johnston H; Shelbourne PF; Li XJ
Nat Genet; 2000 Aug; 25(4):385-9. PubMed ID: 10932179
[TBL] [Abstract][Full Text] [Related]
37. Huntingtin fragments that aggregate go their separate ways.
DiFiglia M
Mol Cell; 2002 Aug; 10(2):224-5. PubMed ID: 12191468
[TBL] [Abstract][Full Text] [Related]
38. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity.
Khoshnan A; Ko J; Watkin EE; Paige LA; Reinhart PH; Patterson PH
J Neurosci; 2004 Sep; 24(37):7999-8008. PubMed ID: 15371500
[TBL] [Abstract][Full Text] [Related]
39. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
40. DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates.
Illuzzi J; Yerkes S; Parekh-Olmedo H; Kmiec EB
J Neurosci Res; 2009 Feb; 87(3):733-47. PubMed ID: 18831068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
